ERBB2 and breast cancer: PD-L1 protein expression according to subtypes was lower in BCBM than BC and higher than N-CNS (Table 2) with ER-positive/HER2-negative (23%), ER-positive/HER2-positive (27%), ER-negative/HER2-positive (57%).